Indian pharmaceutical laboratory Bharat Biotech reported that the test results showed that vaccination is effective against variants of coronovirus
The Indian pharmaceutical laboratory Bharat Biotech told Wednesday (3) that its vaccine “Kovaxin”, highly criticized for being launched before the final tests, reached an efficiency of about 81% in prevention against Kovid-19.
The effectiveness of Bharat Biotech’s “Kovaxin” raised questions from medical staff after it was authorized by authorities on an emergency basis in January, although its Phase 3 trials in the final phase before the final phase are yet to be completed.
“Kovaxin (not only) exhibits a trend towards high clinical efficacy against Kovid-19, but also significant immunogenicity (the ability to induce an antigen) against unexpectedly arising variants.” Said Krishna Ella, president of Bharat Biotech.
The company stated that “serious adverse effects, requiring medical assistance, were at very low levels and were balanced between vaccine and place groups.”
Kovacsin, along with Kovishield from AstraZeneca / Oxford, manufactured in India, are the two authorized vaccines in the country.
The lack of data on covaxin, when the vaccination campaign began in mid-January, aroused suspicion, as members of health workers, including doctors, refused to vaccinate.
Prime Minister Narendra Modi received a dose of Kovaxin on Monday, when the vaccine was extended to more than 60 people and more than 45 critical conditions.
abh / grk / st / age / mb / mr
—
In times of disintegration and epidemic, the newspaper Time Strengthens the commitment to quality, professionalism and Minas Gerais journalism. Our newsroom produces responsible and reliable information every day. Keep supporting us. Please sign on time.
